Pentixapharm Holding AG

NX-5948, Nurix Therapeutics’ treatment for relapsed or refractory chronic lymphocytic leukemia, and Ga68-PentixaFor, Pentixapharm’s radiodiagnostic for primary aldosteronism, are the latest investigat

In late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre

The surge of interest in radiopharmaceuticals for both diagnostics and therapeutics is likely to prove very beneficial for Germany’s PentixaPharm GmbH which has a promising treatment for CNS lymphom

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sionna Gets CF Compounds AbbVie License